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The bioactivity of matrix metalloproteinases was studied in tissues from colorectal cancer patients by means of both
quantitative gelatin zymography and a ﬂuorometric activity assay. Next to paired samples of tumour tissue and distant normal
mucosa (n=73), transitional tissue was analysed from a limited (n=33) number of patients. Broad-spectrum matrix
metalloproteinase activity and both the active and latent forms of the gelatinases matrix metalloproteinase-2 and -9 were
higher in tumour than in normal mucosa. The ratio’s between active and latent forms of matrix metalloproteinase-2 and -9
were highest in tumour tissue and normal mucosa, respectively. Matrix metalloproteinase-2 levels, both active and latent
forms, correlated inversely with stage of disease, the tumours without synchronous distant metastases containing signiﬁcantly
(P=0.005) more active matrix metalloproteinase-2 than the others. At much lower levels of activity, the same trend was
observed in distant normal mucosa. The level of latent form of matrix metalloproteinase-9 in tumour depended on tumour
location. Neither the active form of matrix metalloproteinase-9 nor broad-spectrum matrix metalloproteinase activity in
tumour tissue did correlate with any of the clinicopathological parameters investigated. The results demonstrate explicit
differences between the activity of matrix metalloproteinase-2 and -9, indicating different roles for both gelatinases in tumour
progression. Such data are necessary in order to develop rational anti-cancer therapies based on inhibition of speciﬁc matrix
metalloproteinases.
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Proteinase activity is an important feature in a multitude of
physiological and pathological processes. Proteinases are normally
strictly regulated in order to prevent undesired degradation of
tissue components. In pathological processes like arthritis, period-
ontal disease, liver ﬁbrosis, cardiovascular disease and cancer, the
regulation of proteinase activity is disturbed (Nagase and Woess-
ner, 1999). In cancer, degradation of the extracellular matrix is a
key event in tumour cell invasion and metastasis. Various members
of the matrix metalloproteinase (MMP) family have been shown to
play an important role in these processes, for instance by facilitat-
ing the entry of tumour cells into the bloodstream, angiogenesis,
tumour cell establishment and growth (Curran and Murray,
2000; Nelson et al, 2000). A good understanding of the expression
pattern of the various MMPs in speciﬁc types of cancer may
provide a basis for the development of new therapeutic strategies.
For this purpose, data on the activities of individual MMPs in
tumour tissue are needed.
In a number of studies a positive correlation has been demon-
strated between MMP expression and tumour invasion and
metastasis. Data pertain to different types of cancer located in
various organs (Curran and Murray, 2000). The assay methods
used vary widely and include analysis of mRNA, protein content
and actual proteinase activity. In colorectal cancer (CRC) most
of the data are on mRNA, which is upregulated in tumour cells
and/or tumour stroma, if compared to normal healthy tissue. For
instance, upregulation of mRNA has been reported for MMP-2
(Pyke et al, 1993), MMP-7 (Mori et al, 1995), MMP-9 (Zeng et
al, 1996), MMP-11 (Thewes et al, 1996), MMP-12 (Yang et al,
2001) and MMP-14 (Sardinha et al, 2000). In the immunohisto-
chemical detection of MMPs the focus has been on the analysis
of MMP localisation. Correlations have been described between
MMP-1 immunoreactivity and survival (Murray et al, 1996) and
also between stage of disease and immunoreactivity for MMP-1
(Shiozawa et al, 2000), MMP-2 (Levy et al, 1991) and MMP-7
(Adachi et al, 1999). These studies measure MMP immunoreactiv-
ity without discrimination between latent proenzyme and activated
enzyme. Ultimately, quantitative data on proteinase activity are
most relevant for determining the biological role of MMPs in
tumour progression.
Quantitative gelatin zymography allows the simultaneous
measurement of the latent and active forms of the gelatinases
MMP-2 and MMP-9. In recent years, a limited number of studies
used zymography to investigate the presence of the gelatinases in
tissue samples collected from patients operated for CRC. To some
degree, all show enhanced gelatinase levels in tumour tissue, at least
for the latent forms of MMP-2 and MMP-9. However, some
studies (Liabakk et al, 1996; Parsons et al, 1998) have not quanti-
ﬁed active MMP-9, while others (Garbett et al, 1999a; Zeng et al,
1999; Baker et al, 2000) do not report speciﬁc activities but rather
the absence or presence of the various enzyme forms. A consistent
quantiﬁcation of both the latent and active forms – and their
ratio – of both gelatinases in matched tumour and normal tissue
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www.bjcancer.comis still lacking. Here, we supply these data on samples from a series
of CRC patients, which is also large enough to investigate correla-
tions with clinicopathological parameters. In a number of cases we
have also measured activities in transitional tissue containing the
invasive edge. In addition to quantitative gelatin zymography, we
have used a recently developed broad-spectrum bioassay MMP
activity using an internally quenched ﬂuorogenic peptide substrate.
MATERIALS AND METHODS
Patients and tissue samples
Seventy-three patients with CRC were included in this study. The
paired samples of tumour tissue (n=73), transitional tissue
(n=33) and distant normal mucosa (n=73) were collected immedi-
ately after surgical resection for primary CRC. Macroscopically vital
tumour tissue from the protruding luminal part of the tumour was
harvested by a pathologist. Transitional tissue contained the inva-
sive edge on the luminal side including both tumour and normal
tissue. Normal colonic mucosa samples were taken at least 5 cm
away from the tumour.
Randomly selected samples were analysed histologically to
conﬁrm their cellular content. Samples of patients that received
pre-operative chemo- or radiotherapy were excluded from the
study. All patients provided informed consent and the study was
approved by the institutional ethical committee. The patients’ clin-
icopathological characteristics were determined and used to
compose various groups for comparison (c.f. Table 2). Tumours
were designated mucinous when signiﬁcant parts of the tumour
contained clusters of enlarged mucin producing cells. Tumour
staging was according to the current TNM classiﬁcation, stage I
(T1-2N0M0), II (T3-4N0M0), III (TxN1-3M0) and IV (TxNxM1)
corresponding to Dukes’ stage A, B, C and D, respectively.
Tissue samples were stored in liquid nitrogen and mechanically
disaggregated using a Micro-Dismembrator (Braun), yielding
homogenous samples. The pulverised samples were extracted
(40 ml per mg tissue) in buffer (0.5 M Tris, 0.2 M NaCl, 10 mM
CaCl2 and 1% Triton X-100) for 15 min and freeze–thawed twice.
After centrifugation (18000 r.p.m., 30 min, 48C) the supernatant
was dialysed twice (20 h, 48C) against a buffer containing 5 mM
CaCl2,5 0 m M Tris-HCl and 0.2 M NaCl to remove Triton and
the excess of salt. Tissue extracts were stored at 7808C until use.
Protein determination
Protein content was determined in tissue extracts using the
bicinchoninic protein assay from Pierce (Rockford, IL, USA). To
each extract of 20 ml, 130 ml buffer (50 mM Tris, 0.2 mM NaCl,
5m M CaCl2, pH 7.5) and 2 ml of bicinchoninic acid solution
was added. Following incubation for 30 min at 378C the absor-
bance was read at 550 nm. Bovine serum albumin was used as a
standard.
Gelatin zymography
Gelatin zymography was performed to quantify the presence of
both activated and latent forms of the gelatinases MMP-2 (gelati-
nase A) and MMP-9 (gelatinase B) in the tissue extracts
(Heussen and Dowdle, 1980; Hofmann et al, 1999). Each extract
was diluted 1:1 with sample buffer (0.125 M Tris-HCl, pH 6.8,
17.4% (w v
71) glycerol, 4% sodium dodecylsulphate (SDS) and
0.01% bromophenol blue) and heated at 608C for 20 min. After
centrifugation for a few seconds 5 ml aliquots were loaded on a
7.5% (w v
71) standard Laemmli SDS-polyacrylamide gel contain-
ing 2 mg ml
71 gelatin (Type A: from Porcine Skin, Sigma) as a
substrate. Gels were electrophoresed at 15 mA per gel while stack-
ing and at 20 mA per gel during the separating phase until the
bromophenol blue stained front reached the bottom of the gel.
Collagenase from Clostridium histolyticum (Type VII, Sigma) was
electrophoresed on each gel as an internal standard. After running,
the gels were washed three times in 2.5% (v v
71) Triton X-100 for
10 min at room temperature to remove SDS. After washing twice
in a buffer containing 50 mM Tris-HCl, 5 mM CaCl2 and 0,1%
Triton X-100 (pH 7.8), the gels were incubated overnight at
378C in the same buffer under gentle agitation. Zymograms were
stained for 45 min with 0.25% (w v
71) Coomassie Brilliant Blue
R250 dissolved in 40% methanol and 10% glacial acetic acid. Gels
were destained twice for 10 min in the same solution without
Coomassie Blue. Proteolytic activities were visualised by clear zones
against a dark blue background indicating lysis of gelatin. Loading
of the gels was such that proteinase activity was linear with the
gelatin lysis. Quantiﬁcation of the proteinase activities, which were
expressed as arbitrary units per mg protein on the basis of size of
the lysed area and intensity, was performed using a Sharp JX-330
scanner and Imagemaster ID software (Amersham Pharmacia
Biotech, Uppsala, Sweden). In-between comparison of values,
obtained on different gels, was performed using the internal stan-
dard that was present on each gel. The presence of true MMP
activity was conﬁrmed by adding 10 mM EDTA or 1 mM 1,10'
phenanthroline, both MMP inhibitors, to the buffers used after
electrophoresis. Also human recombinant MMP-2 (1 ng per lane)
and -9 (0.5 ng per lane; Oncogene Research Products, Cambridge,
MA, USA) were added sometimes to compare their location with
endogenous activities (e.g. Figure 1). Activation of recombinant
proform MMPs was achieved by incubation with 1 mM p-amino-
phenylmercuric acetate (APMA).
Fluorometric MMP activity assay
Broad-spectrum MMP activity was determined in 71 out of 73
CRC patient samples (in two cases insufﬁcient sample was left after
zymography to perform the activity assay) using the quenched
ﬂuorogenic peptide substrate TNO211-F (Dabcyl-Gaba-Pro-Gln-
Gly-Leu-Cys(Fluorescein)-Ala-Lys-NH2) essentially as described
previously (Beekman et al, 1999; DeGroot et al, 2001). The
substrate is mainly cleaved by the gelatinases (MMP-2 and -9)
and collagenase 3 (MMP-13) and to a lesser extent by collagenase
2 (MMP-8) and membrane-bound metalloproteinase (MT1–
MMP). As such, conversion of this substrate mainly reﬂects gelati-
nolytic activity. In short, substrate hydrolysis by tissue extracts was
determined in the presence of EDTA-free general proteinase inhibi-
tor Complete (Roche Molecular Biochemicals, Indianapolis, IN,
USA) to prevent conversion of TNO211-F by proteinases other
than MMPs. Further improvement of the assay speciﬁcity for
MMPs was achieved by determining the difference in substrate
conversion in presence and absence of synthetic MMP inhibitor
BB94 (10 mM). The rate of substrate conversion (RFU per s; relative
ﬂuorescence units per second) at 308C( lex: 485 nm, lem: 530 nm;
Cytoﬂuor4000, PerSeptive Biosystems) was normalised to the
amount of protein present in the tissue extract and expressed as
RFU per s per mg protein. All samples and reagents were diluted
in buffer containing 50 mM Tris (pH 7.5), 5 mM CaCl2, 150 mM
NaCl, 1 mM ZnCl2, 0.01% Brij-35 and 0.02% NaN3.
Statistical analysis
Comparisons between MMP levels in matched tumour tissue, tran-
sitional tissue and distant normal mucosa were performed using
the Friedman two-way ANOVA. As a post-test procedure for pair-
wise comparisons Dunn’s post-test was used. The relationship
between MMP levels and clinicopathological parameters was
analysed using the Mann–Whitney U-test when comparing data
between two groups; Kruskal–Wallis test was used when compar-
ing more than two groups, with, in-between comparisons using
Dunn’s post-test. Differences were considered statistically signiﬁ-
cant at the P50.05 level.
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Proteinase activity by gelatin zymography
Seventy-three paired tissue samples of CRC tumour tissue and
matching normal mucosa were extracted and analysed by quanti-
tative gelatin zymography. In addition, gelatinase activity was also
determined in transitional (tumour to normal) tissue which
includes the invasive edge. Figure 1 shows a zymogram containing
tissue extracts from three CRC patients, representative for all
samples investigated. Clearly, the extracts contained multiple
proteinase species of varying molecular weight exhibiting gelati-
nase activity. All were completely inhibited by EDTA (not
shown) conﬁrming their status as metalloproteinases. Comparison
with the puriﬁed MMPs showed the presence of proMMP-9
(92 kDa), active MMP-9 (82 kDa), proMMP-2 (72 kDa) and
active MMP-2 (62 kDa). The lytic bands of high molecular weight
forms, found at approximately 220 and 135 kDa, closely corre-
lated with both each other (r=0.96) and with those of
proMMP-9 (r=0.97 and 0.96 for the 220 and 135 kDa bands
respectively).
All bands representing active and latent forms of MMP-2 and -9
were quantiﬁed and their gelatinolytic activity (on basis of protein)
was calculated. There was a signiﬁcantly higher level of active
MMP-2, proMMP-2, active MMP-9 and proMMP-9 in tumour
tissue compared to normal mucosa (n=73; P50.001, P50.001,
P50.01 and P50.001 respectively) (Figure 2). Active MMP-2,
proMMP-2 and proMMP-9 were also higher in transitional tissue
than in normal mucosa (n=33; P50.001, P50.01, P50.001
respectively), but active MMP-9 was not. Median values in tumour
and transitional tissue were essentially the same. Table 1 shows the
relative increase in MMP activity in tumour over normal tissue: the
median tumour to normal ratio was highest (8.6) for active MMP-
2 and lowest (1.7) for proMMP-2.
Active MMP-2 and MMP-9 were not detectable in six and four
samples from normal mucosa, respectively. In all other samples,
levels of both pro- and active enzymes could be measured. The
separate quantiﬁcation of both the proenzyme and active enzyme
also allowed the calculation of the ratio active/proenzyme in the
three different tissues (Figure 3). In normal mucosa, the ratio
was three times higher (P50.0001) for MMP-9 than for MMP-2.
For MMP-2 this ratio increased ﬁve-fold (P50.001) in tumour
tissue and four-fold (P50.001) in transitional tissue, as compared
to normal mucosa. In contrast, for MMP-9 the ratio was highest in
normal mucosa and decreased (P50.05) in the samples containing
tumour tissue.
Correlation between MMP activity and clinicopathological
parameters
The relations between clinicopathological parameters and the
levels of active and proform MMP-2 and -9 in tumour tissue
are shown in Table 2. A number of correlations was found for
MMP-2 but only one for MMP-9. ProMMP-9 levels showed a
signiﬁcant correlation with tumour location (P=0.040). Rectum
tumours showed the lowest levels of proMMP-9 whereas the left
colon showed the highest levels. Neither age, tumour size, histo-
logical differentiation, tumour cell mucin, T stage nor lymph
node involvement correlated with gelatinolytic MMP activity. In
normal mucosa male patients displayed higher levels of
proMMP-2 compared to female patients (P=0.011), but in
tumour tissue no such difference was seen. Comparison between
primary tumours with and without synchronous liver metastasis
showed that tumours with liver metastasis (TxNxM1) had signiﬁ-
cantly lower activity of both active MMP-2 (P=0.005) and
proMMP-2 (P=0.009) than those without liver metastasis
(TxNxM0). These differences were also observed in distant normal
mucosa, but statistical signiﬁcance was only reached for the acti-
vated form of MMP-2 (P=0.011). The absolute activity of these
MMP-2 levels in normal mucosa were, however, much lower
(approximately 10 times) than those in tumour tissue. The active
to proenzyme ratio of MMP-2 did also differ with this parameter.
In both tumour and distant normal mucosa the ratio was signiﬁ-
cantly lower in the TxNxM1-group than in the TxNxM0-group
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mmp-2 mmp-9
–         +          –        +              T         T–N     N           T       T–N     N         T     T–N      N
1 2 3
MMP-9 heterodimer
(220 kDa)
MMP-9 homodimer
(135 kDa)
ProMMP-9 (92 kDa)
Active MMP-9 (82 kDa)
ProMMP-2 (72 kDa)
Active MMP-2 (62 kDa)
Figure 1 Proteolytic MMP activity in human CRC tissue extracts detected by quantitative gelatin zymography. MMP-2 (7), gelatinolytic activity of re-
combinant proMMP-2; MMP-2 (+), APMA-activated recMMP-2; MMP-9 (7), recombinant proMMP-9; MMP-9 (+), APMA activated recMMP-9; T, tumour;
T–N, transitional (tumour to normal) tissue; N, distant normal mucosa; 1–3, case numbers of three representative patients. Positions of active MMP-2
(62 kDa), proMMP-2 (72 kDa), active MMP-9 (82 kDa) and proMMP-9 (92 kDa) are indicated by arrows. Recombinant MMP-2 and -9 were applied in
doses of 1 and 0.5 ng per lane, respectively.
Table 1 Tumour to normal ratio of MMP activity in CRC
Tumour to normal ratio
n Median Range
Active MMP-2 67
a 8.6 0.0–947.4
ProMMP-2 73 1.7 0.3–13.1
Active MMP-9 69
a 2.0 0.0–351.9
ProMMP-9 73 4.0 0.1–35.2
MMP activity is expressed in arbitrary units per mg protein.
aPatient data were
excluded when activity in normal mucosa equaled zero.
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with stage of disease, a trend was observed towards lower levels
of active MMP-2 and proMMP-2 with advanced stage of disease
in tumour (P=0.024 and P=0.044 respectively) and in normal
mucosa (P=0.019 and NS respectively). This also applied to the
MMP-2 active to proenzyme ratio in tumour (P=0.028) and
normal mucosa (P=0.002). In detail differences were most explicit
between stage II (T3–4NxM0) and stage IV (TxNxM1) tumours
for active MMP-2 (Figure 4) and the MMP-2 active/proenzyme
ratio (both P50.05).
Fluorometric MMP activity assay
Nearly all samples were also measured with a broad-spectrum
MMP assay, using a substrate, which is mainly recognised by the
gelatinases. Figure 5 shows that overall gelatinolytic MMP activity
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Table 2 Correlation between MMP-2 and -9 activities and clinicopathological parameters
Primary colorectal cancer
MMP-2 MMP-9
Parameter No. of cases
a Active Proform Ratio a/p
b Active Proform Ratio a/p
Sex
Male 43 4.4 15.5 (9.4)
d 0.3 4.4 38.4 0.1
Female 30 3.6 13.9 (6.6) 0.3 6.1 46.1 0.1
P 0.797 0.622 (0.011*) 0.893 0.205 0.262 0.638
Age
550 12 3.6 11.5 0.3 3.8 39.5 0.1
50–70 39 4.3 15.4 0.3 5.1 45.0 0.1
470 22 4.1 14.8 0.3 5.7 38.9 0.1
P 0.747 0.575 0.701 0.722 0.648 0.42
Tumour location
Right 35 3.7 12.3 0.4 5.1 43.8 0.1
Left 8 4.0 13.9 0.3 11.3 125.5 0.1
Sigmoid 21 4.0 14.4 0.3 5.5 43.3 0.1
Rectum 9 5.2 15.6 0.4 2.1 27.2 0.1
P 0.871 0.559 0.75 0.088 0.040* 0.538
Tumour size (cm)
53 5 3.4 18.6 0.3 2.5 24.0 0.1
3–5 29 4.0 13.7 0.4 5.0 38.4 0.1
45 38 4.2 14.7 0.3 6.3 51.1 0.1
P 0.846 0.854 0.858 0.367 0.15 0.39
Tumour differentiation
Moderate 48 4.2 14.2 0.3 5.0 46.1 0.1
Poor 24 3.8 14.2 0.3 5.6 41.9 0.1
P 0.971 0.99 0.599 0.867 0.924 0.971
Mucinous tumours
No 49 3.8 13.7 0.3 5.1 43.8 0.2
Yes 23 5.7 15.2 0.4 6.9 66.0 0.1
P 0.13 0.458 0.156 0.381 0.182 0.966
T stage
Tis 1 0.8 2.4 0.3 2.5 3.7 0.7
T1 4 4.6 15.2 0.3 4.4 58.0 0.1
T2 16 4.0 13.5 0.3 4.9 41.1 0.1
T3 42 4.0 14.2 0.3 5.2 40.5 0.1
T4 10 5.9 13.9 0.3 6.6 104.7 0.1
P 0.792 0.487 0.987 0.723 0.119 0.471
N stage
c
TxN0M0 39 5.3 15.5 0.4 5.5 45.0 0.1
TxN1M0 15 3.7 13.7 0.3 5.2 26.8 0.2
P 0.39 0.946 0.213 0.721 0.145 0.765
Distant metastases
TxNxM0 54 5.0 (0.6) 15.5 0.4 (0.1) 5.4 43.6 0.1
TxNxM1 17 2.4 (0.2) 10.8 0.2 (0.0) 3.6 37.4 0.1
P 0.005* (0.011*) 0.009* 0.007* (0.002*) 0.115 0.293 0.153
Stage of disease
I 15 5.3 (0.7) 16.0 0.4 (0.1) 5.8 44.0 0.1
II 23 6.3 (0.9) 15.5 0.4 (0.1) 5.5 53.0 0.1
III 16 4.1 (0.3) 15.5 0.3 (0.0) 5.9 28.8 0.2
IV 17 2.4 (0.2) 10.8 0.2 (0.0) 3.6 37.4 0.1
P 0.024* (0.019*) 0.044* 0.028* (0.002*) 0.408 0.296 0.422
Mann–Whitney U-Test for comparison of two groups; Kruskal–Wallis Test for comparison of non-parametric data of more than two groups.
aOnly
evaluable cases were included.
bRatio active/proMMP.
cLymph node involvement as a parameter independent of T stage (Tx) excluding distant metas-
tasis (M1).
dData between brackets pertain to normal distant mucosa. Activities (arbitrary units per mg protein) are shown in median values. Statistical
signiﬁcant differences are shown with an * (P50.05).
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(P50.001) tissue than in normal mucosa. In contrast to the MMP-
2 activities as determined by zymography, broad-spectrum MMP
activity in tumour tissue did not correlate signiﬁcantly with any
of the clinicopathological parameters mentioned in Table 2. The
only difference found, was that the transitional tissue of patients
with distant metastatic liver disease (n=5) showed higher activity
(3.9 versus 2.0, medians in arbitrary units, P=0.032) compared to
patients without distant metastases (n=24).
DISCUSSION
The present data show that tumour tissue contains higher levels of
active and proform MMP-2 and -9 than distant normal mucosa in
patients with CRC, with the increase in active MMP-2 being the
most pronounced. The active to proform ratio of MMP-2 is high-
est in tumour tissue, whereas this ratio for MMP-9 is highest in
distant normal mucosa. Furthermore, MMP-2 levels do inversely
correlate with stage of disease.
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Figure 2 A comparison of MMP activity in CRC tumour (n=73), transi-
tional tissue (T–N, n=33) and normal mucosa (n=73). Data are shown for
active MMP-2 (A), proMMP-2 (B), active MMP-9 (C) and proMMP-9 (D).
Horizontal bars represent the median values, boxes represent the inter-
quartile range, vertical lines represent the 10 to 90% range of the observa-
tions. Enzyme activity, as measured by quantitative zymography, is
expressed as speciﬁc activity in arbitrary units per milligram protein. Signiﬁ-
cant differences with normal mucosa: **P50.001; *P50.01.
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Figure 3 Ratio between active enzyme and proenzyme for both MMP-2
and -9. Data were obtained by quantitative gelatin zymography. (A) CRC
tumour tissue; (B) transitional tissue (T–N); (C) normal mucosa. Horizon-
tal bars represent median values, boxes represent the interquartile range,
vertical lines represent the 10 to 90% range of the observations. P values
represent the statistical differences between matched data on the MMP-
2 and MMP-9 ratios.
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British Journal of Cancer (2002) 86(12), 1876–1883 ã 2002 Cancer Research UKThe level of proteinase activity in this study was measured using
gelatin zymography and broad-spectrum MMP substrate hydroly-
sis. Zymography separates the proforms and active forms of
MMPs but the technique will not distinguish between free MMPs
and those complexed with their natural inhibitors, the TIMPs
(Kleiner and Stetler Stevenson, 1994). Zymography, therefore,
yields no absolute values on the levels of active and latent MMPs
in vivo, but rather a representation of the levels of the active and
latent forms in both free and complexed form in the various tissues
studied. The results should always be interpreted keeping this in
mind. The broad-spectrum MMP activity assay, however, does
not measure TIMP-complexed MMP activity. Since levels of TIMPs
have not been determined in this study, one could speculate that
the increased levels of MMP-2 and -9 in tumour will have no
actual biological consequence in the in vivo situation because of
endogenous inhibition.
However, in a recent study it is shown that the level of TIMP-2
protein, when measured with ELISA, is signiﬁcantly lower in color-
ectal tumours than in normal mucosa (Baker et al, 2000). With the
high levels of active MMP-2 present in tumour, total inhibition
seems therefore unlikely. Moreover, using the MMP activity assay
with a ﬂuorogenic peptide substrate, enhanced MMP activity was
observed in tumour tissue. Since this assay would not measure
MMP activity if all MMPs were inhibited by TIMPs this indicated
that indeed the increased MMP activation is not compensated for
by increased TIMP production. Also, the ability of TIMP-1, which
is reported to be upregulated (Baker et al, 2000), to bind with all
MMP-9, can be disputed. TIMP-1 availability should prevent
formation of MMP-9 dimers (Goldberg et al, 1992), while we
found high levels of the homodimer of MMP-9 (220 kDa, Figure
1) and the heterodimer of MMP-9 and NGAL (135 kDa) (Zeng
et al, 1999), indicating that there is unbound MMP-9 left in
tumour tissue.
Gelatin zymography demonstrates that both active and
proMMP-2 and -9 levels are elevated signiﬁcantly in primary
CRC tissue compared to normal mucosa. These observations are
consistent with previous observations on active and proform
MMP-2 and proMMP-9 (Liabakk et al, 1996). The presence of
active MMP-9 has also been described before (Yamagata et al,
1991; Garbett et al, 1999a; Zeng et al, 1999; Baker et al, 2000),
but quantitative measurement in all samples had not been reported
up until now. Active MMP-2 increases more than its proform in
tumour tissue. Thus there is not only more MMP-2 present in
tumour than in normal tissue, but the ratio active to proenzyme
also increases substantially. A similar ﬁnding was reported by
Parsons et al (1998) and McKerrow et al (2000) and supports
the view that the activation of MMP-2 is a crucial step in tumour
invasion. Expression of MMP-2 mRNA in tumour has been
described in stromal ﬁbroblastic cells (Poulsom et al, 1992; Newell
et al, 1994), but MMP-2 protein appears to be localised predomi-
nantly in the cytoplasm of tumour cells (Ring et al, 1997). A cell
membrane-bound metalloproteinase (MT1-MMP), present on
tumour cells, has been shown to activate proMMP-2 (Kikuchi et
al, 2000) and is most likely responsible for anchoring MMP-2 to
these malignant cells. Overexpression of MT1-MMP and enhanced
MMP-2 protein activity may thus be induced in the process of
tumour progression.
In contrast to MMP-2, the proform of MMP-9 increases much
more than active MMP-9 during normal to tumour conversion.
This ﬁnding is new since previous studies reported difﬁculty in
measuring the active form, because of its unstability (Parsons et
al, 1998) or presumed low levels (Liabakk et al, 1996). In CRC it
has been shown that MMP-9 mRNA is expressed in macrophages
especially in the invasive site. Immunoreactivity has been shown
in macrophages and neutrophils but not in tumour cells (Nielsen
et al, 1996; Zeng and Guillem, 1996). It is suggested that MMP-9
levels reﬂect the presence of inﬂammatory inﬁltrate around the
tumour rather than the characteristics of the tumour itself.
However, Parsons et al (1998), did not ﬁnd a correlation between
MMP-9 and the amount of peritumoural lymphocytic inﬁltrates.
Our observation that proMMP-9 increases more than its active
form in tumour tissue may result from induced secretion of large
amounts of proform by macrophages and neutrophils. As yet, we
cannot explain why the activation of the proMMP-9 form to the
active form, as represented by the active to proform ratios, appears
to be lower in the tumour than in normal tissue. However, it
would be unjustiﬁed to conclude from this that the role of
MMP-9 in tumour invasion and progression would be less impor-
tant than that of MMP-2, which shows increased activation in
tumour. MMP-9 may even be a more effective protease than
MMP-2 with respect to substrates in the extracellular matrix, as
it is in vitro for gelatin during zymography. Still, it remains to
be established if MMP-9 plays a signiﬁcant role in tumour progres-
sion in CRC. It is evident, however, that there are signiﬁcant
differences in the state of activation between the gelatinases, which
might be indicative for their different roles in the progression of
cancer.
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Figure 4 Active MMP-2 in primary CRC tissue extracts of stage I (n=15),
II (n=23), III (n=16) and IV (n=17) tumours determined by quantitative
gelatin zymography. Horizontal bars represent median values. Stage II ver-
sus stage IV: P50.05.
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Figure 5 Broad-spectrum MMP activity in CRC tumour (n=71), transi-
tional (T–N; n=29) and normal tissue (n=71) determined by quenched
ﬂuorogenic substrate hydrolysis. Activity is expressed as the rate of sub-
strate conversion on basis of protein. Horizontal bars represent median
values, boxes represent the interquartile range, vertical lines represent
the 10 to 90% range of the observations. *P50.01, **P50.001 versus
normal mucosa.
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nase activity reveals correlations for MMP-2, in particular in
relation to stage of disease. Neither Liabakk et al (1996) nor Parsons
et al (1998) found such a correlation, but these authors have not
included stage IV tumours in their studies. Indeed, in our series activ-
itiesarefoundinstageI,IIandIIItumours similartothoseofParsons
et al (1998), but a signiﬁcantly lower activity of both active and
proMMP-2 is found in metastatic stage IV tumours if compared to
all tumours without distant (c.q. liver) metastases. It has been
suggested that MMP activities in the separate disease stages may vary
because of differences in stromal components surrounding the
tumours (Liabakketal,1996). Althoughthis seemsreasonable in view
of the fact that different cell–cell contacts and speciﬁc cell–matrix
interactions may cause changes in MMP expression (DeClerck,
2000), one would then also expect variations in MMP activity with
depth of invasion. However, we ﬁnd no correlations between MMP
activity and T stage. The ﬁnding that active MMP-2 in normal muco-
sa is also inversely correlated with stage of disease and with distant
metastatic disease is remarkable. Although the activities of active
MMP-2 were much lower, they show a similar trend. This may be
due to the effect of local diffusion or perfusion via lymph or blood
vessels. Previous studies on MMP activities have not compared
normal tissue MMP activities with clinicopathological parameters,
most probably due to difﬁculties measuring these low activity levels.
The observation that in normal mucosa the level of proMMP-2
is higher in males than in females has not been described before.
Its relevance in cancer is doubtful because these differences are seen
in normal tissue only, where activities are very low, and do not
pertain to active MMP-2. Also, the correlations between
proMMP-2 levels and other clinicopathological parameters do
not result from a disbalance in gender.
The correlation between tumour proMMP-9 levels and colonic
location has not been found before. Zeng et al (1996) did not ﬁnd
correlation between MMP-9 mRNA expression and location. This
probably means that the increased presence of the proenzyme is
caused by upregulation at the translational level. While no further
signiﬁcant correlations between MMP-9 activity and clinicopatho-
logical parameters in either tumour or normal tissue were found,
a trend towards lower levels of MMP-9 with advancing stage seems
apparent (Table 2). Using immunohistochemistry such a trend has
also been observed by Takeha et al (1997), who suggest that MMP-
9 is, next to being a tumour-promoting factor, also related to the
host defence mechanism. The host reaction against the tumour
counteracts hematogenous metastasis and local invasive growth.
If so, early or slowly invading and growing tumours may trigger
more explicit effects of this host defence mechanism, in this case
production of MMP-9, than fast and diffuse invading tumours.
We have also performed assays on extracts from transitional
tissue. These samples contain, next to tumour and adjacent normal
tissue, the invasive edge. Since only 33 matched samples were avail-
able, analysis of relations between MMP activity and
clinicopathological parameters is not feasible. Transitional tissue
and tumour tissue contain similar levels of active MMP-2, -9
and broad-spectrum MMP activity, with the ﬁrst and latter being
signiﬁcantly higher than those in distant normal mucosa. One
could speculate that proteinase activity is higher in the invasive
edge than in the tumour centre and that overall activity in the
extract from transitional tissue is lowered by the presence of the
normal tissue. However, it has been reported that the adjacent
‘normal’ mucosa also exhibits increased levels of active MMP-2
and -9 (Yamagata et al, 1991; Poulsom et al, 1992). Thus, any deﬁ-
nite conclusions regarding proteinase activity in the invasive edge
must await further analysis by means of, for instance, microdissec-
tion or in situ zymography.
Broad-spectrum MMP activity was measured with a ﬂuorogenic
substrate assay. As with zymography, increased activity is present in
both tumour and transitional tissue. A variety of MMPs may be
responsible for this observation since the substrate is hydrolysed
by all MMPs that exhibit gelatinolytic activity (e.g. MMP-2, -9
and -13). By the use of a speciﬁc MMP inhibitor as a control in
this activity assay and the use of a general protease inhibitor, only
actual active MMPs are measured and not other proteinases or
protein-inhibitor complexes. This is an important difference with
assays used by others (Garbett et al, 1999b; Baker et al, 2000;
McKerrow et al, 2000). The results obtained here indicate that in
the tumours studied MMP (production and) activation is elevated
compared to the production of TIMPs. This results in an excess of
free, active MMPs, which may contribute to the invasiveness of the
tumour.
In summary, our results show increased levels of MMP activity
in tumour and transitional tissues compared to normal mucosa in
CRC patients. Explicit differences between MMP-2 and MMP-9,
with respect to both levels of active enzyme and correlations with
clinicopathological parameters, strongly suggest different roles for
the gelatinases in tumour progression. The results emphasise the
necessity to collect data on the proteinase activity of individual
MMPs in order to develop suitable intervention strategies.
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